STOCK TITAN

Inhibrx Biosciences Inc - INBX STOCK NEWS

Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.

Overview

Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical company focused on the innovative development of novel biologic therapeutic candidates. Utilizing proprietary modular protein engineering platforms, the company is committed to addressing significant unmet medical needs in oncology and rare diseases through precise, target-centric therapeutic design.

Proprietary Technology and Engineering Excellence

At the heart of Inhibrx Biosciences’ operations is its advanced protein engineering technology. This industry-leading platform enables the development of multivalent formats that allow for precise adjustment of antibody valency. The flexibility of this modular approach provides a tailored agonist function, ensuring each therapeutic candidate is optimized for complex biological targets.

Clinical Pipeline and Therapeutic Candidates

Inhibrx Biosciences has built a robust clinical pipeline featuring a diverse range of novel biologic candidates. These candidates are meticulously engineered using multivalent designs to enhance therapeutic efficacy and safety. The company’s approach is deeply rooted in the application of innovative protein engineering methodologies that help accelerate the path from preclinical research to clinical validation.

Business Model and Market Position

The business model centers on advancing clinical-stage therapeutics using a flexible, data-driven approach. Rather than relying on traditional models, Inhibrx Biosciences emphasizes the use of cutting-edge modular platforms to generate bio-optimized therapeutic candidates. This focus on precision and adaptability not only differentiates the company from its peers but also positions it as a forward-thinking entity in the competitive biopharmaceutical landscape.

Strategic Partnerships and Financial Structuring

Inhibrx Biosciences has secured strategic partnerships and innovative financing solutions to support its clinical programs. Such collaborations provide the company with the necessary capital and operational flexibility to continue its research and development efforts. These partnerships, including tailored term loan facilities from specialized financial institutions, ensure that the company maintains a robust infrastructure for ongoing clinical investigations.

Operational Excellence and Scientific Rigor

The company upholds stringent standards of scientific and operational excellence. Through its proprietary protein engineering techniques and commitment to exhaustive preclinical and clinical evaluations, Inhibrx Biosciences ensures its therapeutic candidates are developed with the highest standards of quality. This rigorous approach reinforces trust and credibility among industry analysts and investors alike.

Expert Insights and Industry Relevance

  • Protein Engineering
  • Biologic Therapeutics
  • Multivalent Formats

By integrating advanced protein engineering with a deep understanding of disease biology, Inhibrx Biosciences continues to innovate in the development of precision-targeted therapies. This expert approach not only augments its clinical pipeline but also contributes to a broader industry narrative of overcoming complex therapeutic challenges in oncology and orphan diseases.

Rhea-AI Summary

Inhibrx, Inc. (NASDAQ: INBX) reported its financial results for Q4 and fiscal year 2022, showing significant increases in cash and cash equivalents, totaling $273.9 million, up from $131.3 million in 2021. R&D expenses rose to $30.5 million in Q4, compared to $18.6 million in the previous year, and net loss widened to $40.9 million or $0.95 per share. Key clinical updates include the initiation of INBRX-101's trial for Alpha-1 Antitrypsin Deficiency expected in April 2023 and promising results from INBRX-105. Despite increased operational costs, the company remains focused on advancing its clinical pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary

Inhibrx, Inc. (NASDAQ: INBX) and NorthStar Medical Radioisotopes have announced a collaboration to develop innovative radiopharmaceuticals targeting cancer treatment. This partnership leverages Inhibrx's optimized single-domain antibodies for targeted alpha therapies and NorthStar’s capacity as a supplier of non-carrier added actinium-225 (Ac-225) and copper-67 (Cu-67). The collaboration aims to enhance the efficacy of targeted therapies while ensuring sufficient supply for clinical and commercial use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
none
-
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the 5th Annual HealthCONx Conference on November 30 at 8:45 a.m. PT. This virtual investor conference will include a live webcast of the presentation, available for at least 60 days on Inhibrx's investor website.

As a clinical-stage biopharmaceutical company, Inhibrx focuses on therapeutics for oncology and rare diseases, employing innovative protein engineering techniques. To learn more, visit www.inhibrx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) reported updated efficacy and safety results from its Phase 1 trial of INBRX-109 for treating chondrosarcoma. Among 33 evaluable patients, the disease control rate was 87.9%, with 14 patients showing clinical benefits lasting over 6 months. The treatment exhibited a median progression-free survival of 7.6 months, with minimal adverse events. INBRX-109 has received Fast Track and orphan drug designations from FDA, highlighting its significance in treating this rare cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary

On November 7, 2022, Inhibrx, Inc. (Nasdaq: INBX) reported its third quarter 2022 financial results, revealing a net loss of $35.3 million, or $0.90 per share, compared to a net loss of $20.6 million, or $0.54 per share in Q3 2021. Cash and equivalents stood at $146.1 million as of September 30, 2022, significantly up from $131.3 million at the end of 2021. The company highlighted progress in its clinical programs, including potential accelerated approval for INBRX-101 and orphan drug designation for INBRX-109.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
-
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, announced its participation in several significant scientific conferences including the ACoP and SITC annual meetings. At ACoP (Oct 30-Nov 2, 2022), they will present a poster on INBRX-101 for Alpha-1 Antitrypsin Deficiency. The SITC (Nov 8-12, 2022) will showcase research on a targeted cytokine. Additionally, Inhibrx will present updates on INBRX-109 for chondrosarcoma at the CTOS meeting (Nov 16-19, 2022). Presentations will be accessible via their investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
conferences
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) announced potential for accelerated approval from the FDA for INBRX-101, a recombinant human AAT-Fc fusion protein, aimed at treating emphysema due to alpha-1 antitrypsin deficiency (AATD). The FDA supports the use of functional AAT serum levels as a surrogate endpoint. All patients tested in the Phase 1 study showed detectable INBRX-101 in bronchoalveolar lavage fluid. Inhibrx plans to begin a registration-enabling trial in Q1 2023, with a recent amendment to its loan agreement enabling $30 million funding upon announcing this regulatory path.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.47%
Tags
-
Rhea-AI Summary

Inhibrx, a clinical-stage biopharmaceutical company, will host a live webcast on October 4, 2022, at 5:30 a.m. PT, to discuss the regulatory pathway for INBRX-101. This treatment targets alpha-1 antitrypsin deficiency (AATD), a rare disease affecting about 100,000 patients in the U.S. INBRX-101 is designed for less frequent dosing compared to current therapies. The Phase 1 study demonstrated safety and efficacy, with no severe adverse events reported. The FDA granted INBRX-101 orphan-drug designation in March 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.47%
Tags
conferences
-
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) announced that the European Commission has granted orphan medicinal product designation to INBRX-109 for treating chondrosarcoma, building on a positive EMA opinion. This designation can lead to benefits like reduced fees and market exclusivity. Chondrosarcoma affects about 2,800 new patients annually in the US and EU, with no approved therapies currently available. INBRX-109 is a DR5 agonist antibody, and the company has initiated a Phase 2 trial, showing promising preliminary results in prior trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) reported its Q2 2022 financial results with a net loss of $37.7 million ($0.97 per share), up from $20.7 million ($0.55 per share) in Q2 2021. The company had $176.4 million in cash and equivalents as of June 30, 2022. Key highlights include a successful Phase 1 trial of INBRX-101 for AAT deficiency and the completion of Phase 1 dose escalation for INBRX-105. The company secured $60 million from Oxford Finance through a loan agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags

FAQ

What is the current stock price of Inhibrx Biosciences (INBX)?

The current stock price of Inhibrx Biosciences (INBX) is $14.1 as of April 2, 2025.

What is the market cap of Inhibrx Biosciences (INBX)?

The market cap of Inhibrx Biosciences (INBX) is approximately 203.0M.

What does Inhibrx Biosciences Inc specialize in?

Inhibrx Biosciences Inc specializes in the development of novel biologic therapeutic candidates using proprietary modular protein engineering platforms.

How does the company utilize protein engineering in its therapies?

The company employs advanced protein engineering to design multivalent formats, allowing precise tuning of therapeutic candidates to optimize target-specific agonist functions.

What are the primary therapeutic focus areas of the company?

Inhibrx Biosciences primarily focuses on addressing unmet needs in oncology and rare or orphan diseases through innovative biologic therapies.

How does Inhibrx differentiate itself from competitors?

The company differentiates itself through its proprietary modular approach to protein engineering, enabling highly customizable and targeted therapeutic solutions that specifically address complex disease biology.

What stage is Inhibrx Biosciences in regarding its clinical pipeline?

Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company, advancing its diverse pipeline through rigorous preclinical studies and clinical trials.

How is the company supporting its clinical development?

It supports its clinical development efforts through strategic partnerships and innovative financial structuring, which provide the necessary capital and operational flexibility for continued R&D.

What advantages does the multivalent format offer?

The multivalent format allows for precise modulation of therapeutic activity, enhancing both efficacy and safety by optimizing the engagement of specific biological targets.

Where can investors find reliable information on Inhibrx Biosciences?

Investors can obtain comprehensive, unbiased insights from trusted sources like Stock Titan, which provides detailed descriptions and analyses of companies like Inhibrx Biosciences.
Inhibrx Biosciences Inc

Nasdaq:INBX

INBX Rankings

INBX Stock Data

202.95M
9.50M
26.96%
70%
8.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LA JOLLA